CN108938611A - New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters - Google Patents
New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters Download PDFInfo
- Publication number
- CN108938611A CN108938611A CN201710365996.XA CN201710365996A CN108938611A CN 108938611 A CN108938611 A CN 108938611A CN 201710365996 A CN201710365996 A CN 201710365996A CN 108938611 A CN108938611 A CN 108938611A
- Authority
- CN
- China
- Prior art keywords
- trishydroxymethylaminomethane
- esters
- animals
- humans
- tris nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OLQJQHSAWMFDJE-UHFFFAOYSA-N 2-(hydroxymethyl)-2-nitropropane-1,3-diol Chemical compound OCC(CO)(CO)[N+]([O-])=O OLQJQHSAWMFDJE-UHFFFAOYSA-N 0.000 title claims abstract description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 241001465754 Metazoa Species 0.000 title claims abstract description 10
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 8
- 150000002148 esters Chemical class 0.000 title claims abstract description 7
- 108010034145 Helminth Proteins Proteins 0.000 claims abstract description 5
- 244000000013 helminth Species 0.000 claims abstract description 5
- 244000000010 microbial pathogen Species 0.000 claims abstract description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 201000010063 epididymitis Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 230000001524 infective effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to new humans and animals antibiotic; Tris Nitro and trishydroxymethylaminomethane and its esters have simple carbon symmetrical structure and three high response hydroxyls; it can infiltrate through intracellular; there is protective effect to multicellular organism cell under a certain concentration, there is extremely strong killing and inhibiting effect to unicellular organism and microorganism.Tris Nitro and trishydroxymethylaminomethane and its esters can replace existing antibiotic for treating the humans and animals of Infective helminth pathogenic microorganisms.With easy to implement.
Description
Technical field: the invention belongs to antibiotic medicine, especially new broad-spectrum high efficacy safely and fast antibiotic.Belong to doctor
Treatment and pharmaceutical field.
Background technique: usual Tris Nitro is as lifeless object disinfectant.It is mainly used for following
Industrial water system is cut in disappear oil, non-protein glue and slurry, to inhibit bacterial reproduction；Trishydroxymethylaminomethane is as alkalinity
Drug is served only for the correction of acid poisoning, and the salt of trishydroxymethylaminomethane also only cooks buffer, they are not yet as anti-
Raw element is used for humans and animals.For humans and animals infection helminth, pathogenic microorganisms be all at present using different antibiotic and
Other medicines are treated, for AIDS, hepatopathy virus etc. not yet specific drug, acute appendicitis based on operative treatment,
The common drugs such as epididymis, prostate are difficult to reach, and mycoplasma, Chlamydia common drug curative effect are also bad.
Simple carbon symmetrical structure that Tris Nitro and trishydroxymethylaminomethane and its esters have and
Three high response hydroxyls can infiltrate through into the cell, have protective effect to multicellular organism cell under a certain concentration, to slender
Born of the same parents' biology and microorganism have extremely strong tag and inhibiting effect.It is especially former to superbacteria, comma bacillus, mycoplasma, clothing
Body, AIDS virus, hepatopathy virus have special efficacy.The therapeutic effects such as the epididymitis reached, prostatitis are difficult to for common drug
Well.Ecphyaditis is even more that As the medicine took effect, the symptoms lessened, does not have to operation.
Summary of the invention: with Tris Nitro and trishydroxymethylaminomethane and its esters, humans and animals are treated
Infect helminth, pathogenic microorganisms.Superbacteria, comma bacillus, mycoplasma, Chlamydia, AIDS disease are infected for treating people
Poison, hepatopathy virus, unicellular parasite.For treating epididymitis, prostatitis, ecphyaditis.
Tris Nitro molecular formula: C4H9NO5
Tris Nitro relative molecular weight: 151.12
Tris Nitro structural formula:
Trishydroxymethylaminomethane molecular formula: C4H11NO3
Trishydroxymethylaminomethane relative molecular weight: 121.14
Trishydroxymethylaminomethane structural formula:
Specific embodiment: dosage, direct mouth are determined by the helminth and microbe species of humans and animals weight and infection
Clothes or injection, immersion etc..
Claims (1)
1. new humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters, for controlling
It treats humans and animals and infects helminth, pathogenic microorganisms.Superbacteria, comma bacillus, mycoplasma, clothing original are infected for treating people
Body, AIDS virus, hepatopathy virus, unicellular parasite.For treating epididymitis, prostatitis, ecphyaditis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710365996.XA CN108938611A (en) | 2017-05-17 | 2017-05-17 | New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710365996.XA CN108938611A (en) | 2017-05-17 | 2017-05-17 | New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108938611A true CN108938611A (en) | 2018-12-07 |
Family
ID=64462342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710365996.XA Pending CN108938611A (en) | 2017-05-17 | 2017-05-17 | New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938611A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6538155B1 (en) * | 1999-03-03 | 2003-03-25 | Steven A. Melman | Method for preparing an EDTA-Tris composition, a composition containing EDTA-Tris and uses therefor |
| CN101849547A (en) * | 2010-06-04 | 2010-10-06 | 内蒙古天晨科技有限责任公司 | High-efficiency fungicide |
| CN102524268A (en) * | 2010-11-18 | 2012-07-04 | 陶氏环球技术有限公司 | Synergistic antimicrobial composition comprising 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane |
-
2017
- 2017-05-17 CN CN201710365996.XA patent/CN108938611A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6538155B1 (en) * | 1999-03-03 | 2003-03-25 | Steven A. Melman | Method for preparing an EDTA-Tris composition, a composition containing EDTA-Tris and uses therefor |
| CN101849547A (en) * | 2010-06-04 | 2010-10-06 | 内蒙古天晨科技有限责任公司 | High-efficiency fungicide |
| CN102524268A (en) * | 2010-11-18 | 2012-07-04 | 陶氏环球技术有限公司 | Synergistic antimicrobial composition comprising 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane |
Non-Patent Citations (1)
| Title |
|---|
| 顾学裘主编, 人民卫生出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides | |
| Cao et al. | Characterization and application of a novel Aeromonas bacteriophage as treatment for pathogenic Aeromonas hydrophila infection in rainbow trout | |
| Sivaramasamy et al. | Enhancement of vibriosis resistance in Litopenaeus vannamei by supplementation of biomastered silver nanoparticles by Bacillus subtilis | |
| Huang et al. | Synthesis and evaluation of polyamine carbon quantum dots (CQDs) in Litopenaeus vannamei as a therapeutic agent against WSSV | |
| Peraza‐Gómez et al. | Probiotic microorganisms and antiviral plants reduce mortality and prevalence of WSSV in shrimp (Litopenaeus vannamei) cultured under laboratory conditions | |
| Pan et al. | Broad antiviral activity in tissues of crustaceans | |
| CN101057971A (en) | Medicine for controlling livestock-poultry virus infectious disease | |
| Pais et al. | Effect of immunostimulants on the haemolymph haemagglutinins of tiger shrimp Penaeus monodon | |
| CN107252475B (en) | The application of natural host defense peptide Alligatorin4 | |
| Pandey | Some medicinal plants to treat fish ectoparasitic infections | |
| CN111363723B (en) | Novel vibrio cholerae bacteriophage and application thereof | |
| WO2017222295A1 (en) | Composition for preventing and treating influenza virus, comprising kimchi- and soybean paste- derived lactic acid bacteria as active ingredient | |
| Prada-Peñaranda et al. | Phage preparation FBL1 prevents Bacillus licheniformis biofilm, bacterium responsible for the mortality of the Pacific White Shrimp Litopenaeus vannamei | |
| CN108938611A (en) | New humans and animals antibiotic Tris Nitro and trishydroxymethylaminomethane and its esters | |
| Leibowitz et al. | Treatment development for systemic Tetrahymena sp. infection in guppies, Poecilia reticulata Peters | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| Salem et al. | Secondary antiviral metabolites from fungi with special reference to coronaviruses | |
| He et al. | Experimental evidence of effective disinfectant to control the transmission of Micropterus salmoides rhabdovirus | |
| Dias et al. | In-vitro immunomodulatory responses and antiviral activities of antimicrobial peptide octominin against fish pathogenic viruses | |
| CN110215452A (en) | Ocean toxin compound and its esters are preparing the application in the latent activation drug of HIV | |
| Bergmann et al. | The application of exopolysaccharides (EPS) can prevent viral disease of fish | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| Brutsaert et al. | Attempts to propagate murine poliomyelitis virus on various intestinal bacteria and protozoa. | |
| CN107261113A (en) | Natural host defense peptide Alligatorin5 application | |
| Tiewcharoen et al. | Activity of chlorpromazine on nfa1 and Mp2CL5 genes of Naegleria fowleri trophozoites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |